GYRE
Gyre Therapeutics, Inc.
Price Chart
Latest Quote
$6.47
+0.34 (+5.55%)
Current Price
| Previous Close | $6.13 |
| Open | $6.15 |
| Day High | $6.51 |
| Day Low | $6.15 |
| Volume | 42,154 |
Stock Information
| Shares Outstanding | 111.49M |
| Total Debt | $823K |
| Cash Equivalents | $49.81M |
| Revenue | $117.05M |
| Net Income | $-6.36M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $721.33M |
| EPS (TTM) | $-0.08 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $546.80M |
| Sales | $117.05M |
| Income | $-6.36M |
| Book/sh | $1.11 |
| Cash/sh | $0.45 |
| Employees | 625 |
Financial Ratios
| Quick Ratio | 3.68 |
| Current Ratio | 4.64 |
| Debt/Eq | 0.60 |
Returns & Margins
| ROA | 1.03% |
| ROE | -3.08% |
| Gross Margin | 95.09% |
| Operating Margin | -30.21% |
| Profit Margin | -5.44% |
Ownership
| Insider Ownership | 86.33% |
| Institutional Ownership | 3.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 107.83 |
| P/S | 6.16 |
| P/B | 5.83 |
Analyst Data
| Recommendation | none |
| Target Price | $18.67 |
Technical Indicators
| SMA20 | $6.00 |
| SMA50 | $6.78 |
| SMA200 | $7.47 |
| RSI | 66.67 |
| ATR | 0.3164 |
| Shares Float | 21.28M |
| Short Float | 8.07% |
| Short Ratio | 18.60 |
| Volatility | 4.92 |
| Rel Volume | 0.49 |
Performance History
| Week | +11.17% |
| Month | +6.77% |
| Quarter | -6.77% |
| 6 Months | -9.26% |
| YTD | -4.99% |
| Year | -16.73% |
| 3 Years | +65.90% |
| 5 Years | -38.79% |
| 10 Years | -86.41% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $6.47 | 42,154 |
| 2026-06-23 | $6.13 | 53,300 |
| 2026-06-22 | $6.13 | 75,700 |
| 2026-06-18 | $6.25 | 85,700 |
| 2026-06-17 | $6.08 | 66,400 |
| 2026-06-16 | $5.82 | 75,400 |
| 2026-06-15 | $5.86 | 57,100 |
| 2026-06-12 | $5.93 | 81,600 |
| 2026-06-11 | $6.06 | 75,100 |
| 2026-06-10 | $5.95 | 71,000 |
| 2026-06-09 | $6.13 | 92,600 |
| 2026-06-08 | $6.05 | 76,600 |
| 2026-06-05 | $6.29 | 137,900 |
| 2026-06-04 | $6.19 | 133,400 |
| 2026-06-03 | $5.69 | 72,500 |
| 2026-06-02 | $5.56 | 120,700 |
| 2026-06-01 | $5.81 | 125,500 |
| 2026-05-29 | $5.91 | 107,700 |
| 2026-05-28 | $5.74 | 96,300 |
| 2026-05-27 | $5.92 | 80,400 |
| 2026-05-26 | $5.94 | 125,900 |
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
đ° Latest News
US High Growth Tech Stocks To Watch
Simply Wall St. âĸ 2026-05-28T17:38:45Z
New Strong Sell Stocks for May 27th
Zacks âĸ 2026-05-27T12:18:00Z
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T11:45:06Z
Exploring Three High Growth Tech Stocks In The US Market
Simply Wall St. âĸ 2026-03-27T17:38:43Z
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Zacks âĸ 2026-03-12T11:10:02Z
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-03-09T21:15:01Z
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
TipRanks âĸ 2026-03-03T13:23:53Z
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires âĸ 2026-03-02T20:58:02ZDay One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-02-25T00:30:04Z
High Growth Tech Stocks in US for February 2026
Simply Wall St. âĸ 2026-02-11T11:38:21Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,416,000 | $3,884,000 | $4,636,000 | $4,793,000 |
| Cost Of Revenue | $5,416,000 | $3,884,000 | $4,636,000 | $4,793,000 |
| Total Revenue | $116,588,000 | $105,757,000 | $113,450,000 | $102,290,000 |
| Operating Revenue | $116,588,000 | $105,757,000 | $113,450,000 | $102,290,000 |
| Expenses | ||||
| Total Expenses | $105,097,000 | $89,528,000 | $94,237,000 | $93,087,000 |
| Other Income Expense | $1,198,000 | $5,442,000 | $-97,222,000 | $-517,000 |
| Other Non Operating Income Expenses | $-1,505,000 | $-1,659,000 | $-1,518,000 | $-517,000 |
| Net Non Operating Interest Income Expense | $1,747,000 | $1,547,000 | $1,044,000 | $726,000 |
| Operating Expense | $99,681,000 | $85,644,000 | $89,601,000 | $88,294,000 |
| Selling And Marketing Expense | $65,179,000 | $57,511,000 | $61,159,000 | $54,238,000 |
| General And Administrative Expense | $20,804,000 | $16,109,000 | $14,662,000 | $17,370,000 |
| Total Other Finance Cost | - | - | $-1,044,000 | $-726,000 |
| Interest Expense | - | - | - | $43,338 |
| Interest Expense Non Operating | - | - | - | $43,338 |
| Other Operating Expenses | - | - | - | $-835,157 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $5,027,000 | $12,085,000 | $-92,933,000 | $2,302,000 |
| Net Interest Income | $1,747,000 | $1,547,000 | $1,044,000 | $726,000 |
| Interest Income | $1,747,000 | $1,547,000 | $1,044,000 | $707,753 |
| Normalized Income | $3,177,337 | $6,610,839 | $-17,326,840 | $2,302,000 |
| Net Income From Continuing And Discontinued Operation | $5,027,000 | $12,085,000 | $-92,933,000 | $2,302,000 |
| Total Operating Income As Reported | $11,487,000 | $16,163,000 | $-67,230,000 | $9,203,000 |
| Net Income Common Stockholders | $5,027,000 | $12,085,000 | $-92,933,000 | $2,302,000 |
| Net Income | $5,027,000 | $12,085,000 | $-92,933,000 | $2,302,000 |
| Net Income Including Noncontrolling Interests | $9,880,000 | $17,898,000 | $-85,480,000 | $4,314,000 |
| Net Income Continuous Operations | $9,880,000 | $17,898,000 | $-85,480,000 | $4,314,000 |
| Pretax Income | $14,436,000 | $23,218,000 | $-76,965,000 | $9,412,000 |
| Special Income Charges | $-4,000 | $-66,000 | $-86,443,000 | $0 |
| Interest Income Non Operating | $1,747,000 | $1,547,000 | $1,044,000 | $707,753 |
| Operating Income | $11,491,000 | $16,229,000 | $19,213,000 | $9,203,000 |
| Gross Profit | $111,172,000 | $101,873,000 | $108,814,000 | $97,497,000 |
| Per Share | ||||
| Diluted EPS | $0.02 | $0.05 | $-1.41 | $0.03 |
| Basic EPS | $0.06 | $0.14 | $-1.41 | $0.03 |
| Other | ||||
| Tax Effect Of Unusual Items | $853,337 | $1,626,839 | $-20,097,840 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $11,308,000 | $10,716,000 | $116,031,000 | $10,332,000 |
| Total Unusual Items | $2,703,000 | $7,101,000 | $-95,704,000 | $0 |
| Total Unusual Items Excluding Goodwill | $2,703,000 | $7,101,000 | $-95,704,000 | $0 |
| Reconciled Depreciation | $2,520,000 | $1,588,000 | $1,114,000 | $1,129,000 |
| EBITDA (Bullshit earnings) | $14,011,000 | $17,817,000 | $20,327,000 | $10,332,000 |
| EBIT | $11,491,000 | $16,229,000 | $19,213,000 | $9,203,000 |
| Diluted Average Shares | $103,180,037 | $102,293,526 | $65,831,675 | $76,583,622 |
| Basic Average Shares | $89,344,622 | $85,094,948 | $65,831,675 | $76,583,622 |
| Diluted NI Availto Com Stockholders | $5,027,000 | $12,085,000 | $-92,933,000 | $2,302,000 |
| Minority Interests | $-4,853,000 | $-5,813,000 | $-7,453,000 | $-2,012,000 |
| Tax Provision | $4,556,000 | $5,320,000 | $8,515,000 | $5,098,000 |
| Gain On Sale Of Ppe | $-4,000 | $-66,000 | $-628,000 | $0 |
| Gain On Sale Of Security | $2,707,000 | $7,167,000 | $-9,261,000 | - |
| Research And Development | $13,698,000 | $12,024,000 | $13,780,000 | $16,686,000 |
| Selling General And Administration | $85,983,000 | $73,620,000 | $75,821,000 | $71,608,000 |
| Other Gand A | $20,804,000 | $16,109,000 | $14,662,000 | $17,370,000 |
| Gain On Sale Of Business | - | $0 | $-2,711,000 | $0 |
| Other Special Charges | - | - | $83,104,000 | - |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $99,879,000 | $61,614,000 | $-17,526,000 | $40,666,000 |
| Total Assets | $166,132,000 | $125,406,000 | $116,539,000 | $84,753,000 |
| Total Non Current Assets | $63,763,000 | $60,620,000 | $59,318,000 | $35,100,000 |
| Other Non Current Assets | $2,492,000 | $3,030,000 | $995,000 | $3,394,000 |
| Non Current Deferred Assets | $6,873,000 | $5,619,000 | $4,695,000 | $4,081,000 |
| Non Current Deferred Taxes Assets | $6,873,000 | $5,619,000 | $4,695,000 | $4,081,000 |
| Investmentin Financial Assets | $23,516,000 | $24,568,000 | $23,431,000 | $7,394,000 |
| Goodwill And Other Intangible Assets | $6,152,000 | $1,705,000 | $1,698,000 | $1,856,000 |
| Other Intangible Assets | $6,152,000 | $1,705,000 | $1,698,000 | $1,856,000 |
| Current Assets | $102,369,000 | $64,786,000 | $57,221,000 | $49,653,000 |
| Other Current Assets | $1,489,000 | $1,436,000 | $1,045,000 | $843,000 |
| Prepaid Assets | $1,338,000 | $1,189,000 | $1,547,000 | $377,000 |
| Inventory | $10,171,000 | $6,337,000 | $4,281,000 | $6,122,000 |
| Receivables | $36,946,000 | $29,153,000 | $16,839,000 | $17,136,000 |
| Other Receivables | $230,000 | $5,191,000 | $1,287,000 | $8,493,000 |
| Notes Receivable | $5,638,000 | $4,373,000 | $389,000 | $1,522,000 |
| Accounts Receivable | $31,078,000 | $19,589,000 | $15,163,000 | $15,738,000 |
| Allowance For Doubtful Accounts Receivable | $-151,000 | $-209,000 | $-41,000 | $-862,000 |
| Gross Accounts Receivable | $31,229,000 | $19,798,000 | $15,204,000 | $109,615,000 |
| Cash Cash Equivalents And Short Term Investments | $52,425,000 | $26,671,000 | $33,509,000 | $25,175,000 |
| Cash And Cash Equivalents | $37,070,000 | $11,813,000 | $33,509,000 | $25,175,000 |
| Non Current Accounts Receivable | - | - | $4,722,000 | - |
| Receivables Adjustments Allowances | - | - | $-41,000 | $-124,000 |
| Non Current Prepaid Assets | - | - | - | $21,730,000 |
| Cash Financial | - | - | - | $163,420,000 |
| Debt | ||||
| Total Debt | $939,000 | $1,598,000 | $409,000 | $613,000 |
| Long Term Debt And Capital Lease Obligation | $303,000 | $885,000 | $199,000 | $121,000 |
| Current Debt And Capital Lease Obligation | $636,000 | $713,000 | $210,000 | $492,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $23,850,000 | $27,004,000 | $102,590,000 | $12,536,000 |
| Total Non Current Liabilities Net Minority Interest | $5,564,000 | $7,488,000 | $82,543,000 | $294,000 |
| Other Non Current Liabilities | $1,448,000 | $7,000 | $49,000 | $55,000 |
| Derivative Product Liabilities | $2,961,000 | $5,668,000 | $17,557,000 | $0 |
| Non Current Deferred Liabilities | $852,000 | $928,000 | $213,000 | $118,000 |
| Current Liabilities | $18,286,000 | $19,516,000 | $20,047,000 | $12,242,000 |
| Current Deferred Liabilities | $111,000 | $156,000 | $79,000 | $167,000 |
| Payables And Accrued Expenses | $17,527,000 | $12,949,000 | $19,110,000 | $10,937,000 |
| Payables | $5,722,000 | $5,285,000 | $10,019,000 | $4,828,000 |
| Other Payable | $2,431,000 | $2,119,000 | $3,241,000 | $2,487,000 |
| Total Tax Payable | $2,940,000 | $2,831,000 | $5,054,000 | $2,101,000 |
| Income Tax Payable | $2,940,000 | $2,831,000 | $5,054,000 | $2,101,000 |
| Accounts Payable | $124,000 | $108,000 | $355,000 | $122,000 |
| Other Current Liabilities | - | $4,961,000 | - | - |
| Equity | ||||
| Common Stock Equity | $106,031,000 | $63,319,000 | $-15,828,000 | $42,522,000 |
| Total Equity Gross Minority Interest | $142,282,000 | $98,402,000 | $13,949,000 | $72,217,000 |
| Stockholders Equity | $106,031,000 | $63,319,000 | $-15,828,000 | $42,522,000 |
| Gains Losses Not Affecting Retained Earnings | $2,319,000 | $501,000 | $1,454,000 | $2,268,000 |
| Other Equity Adjustments | $2,319,000 | $501,000 | $1,454,000 | $2,268,000 |
| Retained Earnings | $-68,426,000 | $-73,453,000 | $-85,538,000 | $7,395,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $64,525,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $91,314,007 | $86,307,544 | $76,595,616 | $76,583,622 |
| Share Issued | $91,314,007 | $86,307,544 | $76,595,616 | $76,583,622 |
| Tangible Book Value | $99,879,000 | $61,614,000 | $-17,526,000 | $40,666,000 |
| Invested Capital | $106,031,000 | $63,319,000 | $-15,828,000 | $42,522,000 |
| Working Capital | $84,083,000 | $45,270,000 | $37,174,000 | $37,411,000 |
| Capital Lease Obligations | $939,000 | $1,598,000 | $409,000 | $613,000 |
| Total Capitalization | $106,031,000 | $63,319,000 | $-15,828,000 | $42,522,000 |
| Minority Interest | $36,251,000 | $35,083,000 | $29,777,000 | $29,695,000 |
| Additional Paid In Capital | $172,047,000 | $136,185,000 | $68,179,000 | $32,795,000 |
| Capital Stock | $91,000 | $86,000 | $77,000 | $64,000 |
| Common Stock | $91,000 | $86,000 | $77,000 | $64,000 |
| Non Current Deferred Revenue | $852,000 | $928,000 | $213,000 | $118,000 |
| Long Term Capital Lease Obligation | $303,000 | $885,000 | $199,000 | $121,000 |
| Current Deferred Revenue | $111,000 | $156,000 | $79,000 | $167,000 |
| Current Capital Lease Obligation | $636,000 | $713,000 | $210,000 | $492,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,000 | $737,000 | $648,000 | $646,000 |
| Current Accrued Expenses | $11,805,000 | $7,664,000 | $9,091,000 | $6,109,000 |
| Dueto Related Parties Current | $227,000 | $227,000 | $1,369,000 | $118,000 |
| Investments And Advances | $23,516,000 | $24,568,000 | $23,431,000 | $7,394,000 |
| Available For Sale Securities | $23,516,000 | $24,568,000 | $23,431,000 | $7,394,000 |
| Net PPE | $24,730,000 | $25,698,000 | $23,777,000 | $18,375,000 |
| Accumulated Depreciation | $-7,576,000 | $-5,599,000 | $-4,265,000 | $-3,998,000 |
| Gross PPE | $32,306,000 | $31,297,000 | $28,042,000 | $22,373,000 |
| Construction In Progress | $765,000 | $222,000 | $7,875,000 | $4,851,000 |
| Other Properties | $1,131,000 | $1,818,000 | $489,000 | $666,000 |
| Machinery Furniture Equipment | $10,841,000 | $10,277,000 | $7,389,000 | $5,685,000 |
| Buildings And Improvements | $19,569,000 | $18,980,000 | $12,289,000 | $10,837,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,894,000 | $2,614,000 | $1,365,000 | $1,399,000 |
| Work In Process | $6,307,000 | $2,929,000 | $1,997,000 | $3,667,000 |
| Raw Materials | $970,000 | $794,000 | $919,000 | $1,056,000 |
| Other Short Term Investments | $15,355,000 | $14,858,000 | $0 | $10,597,000 |
| Leases | - | - | $0 | $334,000 |
| Land And Improvements | - | - | $1,493,000 | $1,559,000 |
| Inventories Adjustments Allowances | - | - | - | $-62,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-913,000 | $-6,769,000 | $17,306,000 | $5,679,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,010,000 | $-3,641,000 | $25,892,000 | $10,677,000 |
| Cash Flow From Continuing Operating Activities | $1,010,000 | $-3,641,000 | $25,892,000 | $10,677,000 |
| Operating Gains Losses | $-2,587,000 | $-6,825,000 | $13,953,000 | $255,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,923,000 | $-3,128,000 | $-8,586,000 | $-4,998,000 |
| Investing Cash Flow | $-474,000 | $-19,884,000 | $-19,760,000 | $-13,814,000 |
| Cash Flow From Continuing Investing Activities | $-474,000 | $-19,884,000 | $-19,760,000 | $-13,814,000 |
| Net Other Investing Changes | - | - | $-124,000 | $-7,290,885 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $23,509,000 | $773,000 | $2,500,000 | $0 |
| Financing Cash Flow | $24,378,000 | $2,102,000 | $2,500,000 | $0 |
| Cash Flow From Continuing Financing Activities | $24,378,000 | $2,102,000 | $2,500,000 | $0 |
| Net Other Financing Charges | $-1,487,000 | $-536,000 | - | - |
| Net Common Stock Issuance | $23,509,000 | $773,000 | $0 | - |
| Common Stock Issuance | $23,509,000 | $773,000 | $0 | - |
| Net Preferred Stock Issuance | - | $0 | $2,500,000 | $0 |
| Preferred Stock Issuance | - | $0 | $2,500,000 | $0 |
| Cash Dividends Paid | - | - | - | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $5,621,000 | $8,518,000 | $6,346,000 | - |
| End Cash Position | $37,070,000 | $11,813,000 | $33,509,000 | $25,175,000 |
| Beginning Cash Position | $11,813,000 | $33,509,000 | $25,175,000 | $30,203,000 |
| Effect Of Exchange Rate Changes | $343,000 | $-273,000 | $-298,000 | $-1,891,000 |
| Changes In Cash | $24,914,000 | $-21,423,000 | $8,632,000 | $-3,137,000 |
| Proceeds From Stock Option Exercised | $2,356,000 | $1,865,000 | $0 | - |
| Net Investment Purchase And Sale | $1,419,000 | $-15,471,000 | $-15,735,000 | $-7,484,000 |
| Sale Of Investment | $15,429,000 | $0 | - | $0 |
| Purchase Of Investment | $-14,010,000 | $-15,471,000 | $-15,735,000 | $-7,484,000 |
| Net Business Purchase And Sale | $0 | $-1,686,000 | $4,021,000 | $-1,332,000 |
| Purchase Of Business | $0 | $-1,686,000 | $-1,566,000 | $-1,332,000 |
| Net Intangibles Purchase And Sale | $-733,000 | $-813,000 | $-69,000 | $-13,000 |
| Purchase Of Intangibles | $-733,000 | $-813,000 | $-69,000 | $-13,000 |
| Net PPE Purchase And Sale | $-1,160,000 | $-1,914,000 | $-7,853,000 | $-4,985,000 |
| Sale Of PPE | $30,000 | $401,000 | $664,000 | $0 |
| Purchase Of PPE | $-1,190,000 | $-2,315,000 | $-8,517,000 | $-4,985,000 |
| Change In Working Capital | $-15,554,000 | $-15,688,000 | $7,458,000 | $-7,797,000 |
| Change In Other Working Capital | $25,000 | - | - | - |
| Change In Other Current Liabilities | $-791,000 | $-793,000 | $-575,000 | $-429,000 |
| Change In Payables And Accrued Expense | $1,002,000 | $-3,991,000 | $5,066,000 | $458,000 |
| Change In Accrued Expense | $946,000 | $-1,497,000 | $1,446,000 | $1,914,000 |
| Change In Payable | $56,000 | $-2,494,000 | $3,620,000 | $-1,456,000 |
| Change In Account Payable | $13,000 | $-245,000 | $192,000 | $-112,000 |
| Change In Tax Payable | $44,000 | $-2,166,000 | $3,003,000 | $-1,344,000 |
| Change In Income Tax Payable | $44,000 | $-2,166,000 | $3,003,000 | $-1,344,000 |
| Change In Prepaid Assets | $-206,000 | $520,000 | $-82,000 | $973,000 |
| Change In Inventory | $-3,631,000 | $-2,139,000 | $1,747,000 | $-879,000 |
| Change In Receivables | $-11,953,000 | $-9,285,000 | $1,302,000 | $-7,920,000 |
| Changes In Account Receivables | $-10,806,000 | $-5,257,000 | $285,000 | $-7,920,000 |
| Other Non Cash Items | $766,000 | $-613,000 | $82,787,000 | $226,000 |
| Stock Based Compensation | $7,157,000 | $831,000 | $7,281,000 | $13,366,000 |
| Asset Impairment Charge | $-63,000 | $170,000 | $-61,000 | $22,000 |
| Deferred Tax | $-1,109,000 | $-1,002,000 | $-1,160,000 | $-838,000 |
| Deferred Income Tax | $-1,109,000 | $-1,002,000 | $-1,160,000 | $-838,000 |
| Depreciation Amortization Depletion | $2,520,000 | $1,588,000 | $1,114,000 | $1,129,000 |
| Depreciation And Amortization | $2,520,000 | $1,588,000 | $1,114,000 | $1,129,000 |
| Depreciation | $2,520,000 | $1,588,000 | $1,114,000 | $1,129,000 |
| Earnings Losses From Equity Investments | $77,000 | $37,000 | $1,314,000 | $251,000 |
| Gain Loss On Investment Securities | $-2,668,000 | $-6,928,000 | $9,300,000 | - |
| Gain Loss On Sale Of PPE | $4,000 | $66,000 | $628,000 | $4,000 |
| Net Income From Continuing Operations | $9,880,000 | $17,898,000 | $-85,480,000 | $4,314,000 |
| Sale Of Business | - | $0 | $5,587,000 | $0 |
| Gain Loss On Sale Of Business | - | $0 | $2,711,000 | $0 |
| Repayment Of Debt | - | - | - | $-466,279 |
| Interest Paid Cff | - | - | - | $-43,338 |
| Net Issuance Payments Of Debt | - | - | - | $-466,279 |
| Net Long Term Debt Issuance | - | - | - | $-466,279 |
| Long Term Debt Payments | - | - | - | $-466,279 |
| Taxes Refund Paid | - | - | - | $-6,143,232 |
| Provisionand Write Offof Assets | - | - | - | $21,017 |
| Amortization Cash Flow | - | - | - | $468,453 |
| Amortization Of Intangibles | - | - | - | $468,453 |
Fetched: 2026-06-24